Naoya Fujita

Aichi Medical University — Japan

Medicine · Health Sciences

70h-index15.0kcitations428works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(60), Cancer Mechanisms and Therapy(46), Cancer therapeutics and mechanisms(39), PI3K/AKT/mTOR signaling in cancer(35), Lymphatic System and Diseases(31)

Publications428 total

Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction and eGFR Stabilization in Pediatric Patients: Phase 3 VALIANT Subgroup Analysis
Journal of the American Society of Nephrology·2025
Investigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS)
Clinical and Experimental Nephrology·2025Open Access
Engineering a multilayered 3D stromal barrier model for quantitative analysis of T cell infiltration and cytotoxicity
Acta Biomaterialia·2025
Targeted treatment with pegcetacoplan for adolescents with C3G or primary (idiopathic) IC-MPGN in the VALIANT phase 3 trial
Immunobiology·2025· 1 citedOpen Access
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
npj Precision Oncology·2025· 10 citedOpen Access
STUDY ON CHARACTERISTICS OF RIP CURRENT GENERATION AT POCKET BEACH USING AI-BASED RIP CURRENT DETECTION DATA
Japanese Journal of JSCE·2025
Coexistence of Intravascular Excess Fluid and Reduced Renal Blood Flow in the Acute Phase of Acute Post-Streptococcal Glomerulonephritis
JMA Journal·2025Open Access
EVALUATING THE ACCURACY OF RIP CURRENT VISUALIZATION USING AUGMENTED REALITY LINKED TO AI-BASED DETECTION
Japanese Journal of JSCE·2025
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
Oncogene·2024· 4 citedOpen Access
SUrvey of renal Biopsy registry database and Anticancer dRUg therapy in Japan (SUBARU-J study)
Clinical Kidney Journal·2024· 3 citedOpen Access
In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissues
Acta Biomaterialia·2024· 5 citedOpen Access
Gear health monitoring using smart gears with printed sensor/antenna circuits by running tests
2024
Abstract 4651: A macrocyclic kinase inhibitor overcomes the compound mutations that cause the resistance to all approved EGFR inhibitors in EGFR-positive lung cancer
Cancer Research·2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
npj Precision Oncology·2024· 11 citedOpen Access
In Vitro Throughput Screening of Anticancer Drugs Using Patient-Derived Cell Lines Cultured on Vascularized Three-Dimensional Stromal Tissues
SSRN Electronic Journal·2024Open Access
Idiopathic hypersomnia with a video recording of a spontaneous sleep attack: A case report
2023Open Access
Abstract 4565: Drug screening by layered 3D co-cultured tumor model including vascularized stromal tissue
Cancer Research·2023
Supplementary Figure Legend from The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
2023Open Access
Data from PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation
2023Open Access
Supplementary Fig. S2 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
2023Open Access
page 1 of 22Next →

Frequent Co-authors

Takashi Tsuruo(29), Ryohei Katayama(12), Saori Sato(7), Makoto Nishio(7), Luc Friboulet(6), Noriko Yanagitani(6), Shigeo Sato(6), Sumie Koike(6), Yukinari Kato(6), Tomoko Oh‐hara(6), Alice T. Shaw(5), Jeffrey A. Engelman(5), Mika K. Kaneko(5), Yasushi Okuno(4), Akiko Kunita(4), Motoki Osawa(4), Justin F. Gainor(3), Elizabeth L. Lockerman(3), Mitsugu Araki(3), Kazuhiro Katayama(3)